WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that Jay R. Luly, Ph.D., President and Chief Executive Officer, will
participate in the following investor conferences:
June 18, 2019 at 3:00 p.m. ET – Raymond James Life Sciences and MedTech
Conference, New York City
June 19, 2019 at 9:30 a.m. ET – JMP
Securities Life Sciences Conference, New York City
A live webcast of the presentations will be accessible by visiting the
“Events and Presentations” section on the “Investors” page of Enanta’s
website at www.enanta.com.
A replay of the webcasts will be available following the presentation
and will be archived for approximately 30 days.
About Enanta
Enanta is using its robust, chemistry-driven approach and drug discovery
capabilities to become a leader in the discovery and development of
small molecule drugs for the treatment of viral infections and liver
diseases. Enanta’s research and development efforts are currently
focused on the following disease targets: respiratory syncytial virus
(RSV), non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis
(PBC), and hepatitis B virus (HBV).
Enanta’s research and development activities are funded by royalties
from HCV products developed under its collaboration with AbbVie.
Glecaprevir, a protease inhibitor discovered by Enanta, is now sold by
AbbVie in numerous countries as part of its newest treatment for chronic
hepatitis C virus (HCV) infection. This leading HCV regimen is sold
under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com
for more information.
Contacts
Investor Contact
Carol Miceli
617-607-0710
cmiceli@enanta.com